Examining Trends of Biomarker Testing With the MYLUNG Study in mNSCLC
June 23rd 2022During an interview with Targeted Oncology, Nicholas J. Robert, MD, further discussed the data of the MYLUNG study which he presented in a poster at the 2022 American Society of Clinical Oncology Annual Meeting.
Read More
McKesson Designated by CMS as 2022 Qualified Clinical Data Registry
February 8th 2022With custom QCDR measures identified by physician leaders in The US Oncology Network, McKesson has been received approval from The Centers for Medicare & Medicaid Services (CMS) to participate in the Merit-based Incentive Payment System as a registry.
Read More
monarchE Update Shows Sustained Benefit of Adjuvant Abemaciclib for HR+/HER2- Early Breast Cancer
October 18th 2021New findings from the phase 3 monarchE recently led to an FDA approval for abemaciclib. Joyce O’Shaughnessy, MD, presented the long-term analysis results during an ESMO Virtual Plenary.
Read More
Cumulative Risk Factors May Be Prognostic in Advanced Ovarian Cancer
September 20th 2021In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.
Read More
Genetic Testing Empowers Better Cancer Care, Prevention, and Early Detection
August 13th 2021Today, many community oncology practices routinely employ genetic testing, enabling newly diagnosed patients and their oncologists to make treatment decisions and to formulate preventive strategies based on genetic information.
Read More
Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study
June 15th 2021Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
Read More
Texas Colon & Rectal Specialists Join Texas Oncology and The US Oncology Network
April 2nd 2021Surgical oncology expertise has been expanded to local communities in North Texas after physicians from Texas Colon & Rectal Specialists, a large colorectal cancer practice in North Texas, have joined Texas Oncology, increasing The US Oncology Network’s reach.
Read More
Deciding on an Agent for Prostate Cancer Involves Careful Consideration of Prior Therapy
December 28th 2020Anthony A. Meluch, MD, medical oncologist, Tennessee Oncology, discussed treatment options for high-risk adenocarcinoma of the prostate based on the case of a 75-year-old patient during a Targeted Oncology Case-Based Peer Perspectives event.
Read More